Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
J Infect Chemother. 2012 Feb;18(1):53-8. doi: 10.1007/s10156-011-0283-5. Epub 2011 Jul 20.
Information about the development of febrile neutropenia in patients with solid tumors remains insufficient. In this study, we tried to identify the risk factors for refractory febrile neutropenia in patients with lung cancer. A total of 59 neutropenic fever episodes associated with anti-tumor chemotherapy for lung cancer were retrospectively analyzed. We compared patient characteristics according to their initial response to treatment with antibiotics. For 34 of 59 (58%) episodes a response to initial antibiotics was obtained whereas 25 of 59 (42%) were refractory to treatment. Multivariate analysis demonstrated independent risk factors for refractory febrile neutropenia with lung cancer. These risk factors were the severity of febrile neutropenia (odds ratio (OR) 6.11; 95% confidence interval (CI) 1.85-20.14) and C-reactive protein more than 10 mg/dl (OR 4.39; 95% CI 1.22-15.74). These factors could predict outcome for patients with lung cancer who develop refractory febrile neutropenia.
有关实体瘤患者中性粒细胞减少性发热发展的信息仍然不足。在这项研究中，我们试图确定肺癌患者难治性中性粒细胞减少性发热的危险因素。回顾性分析了 59 例与肺癌抗肿瘤化疗相关的中性粒细胞减少性发热发作。我们根据患者对初始抗生素治疗的反应来比较患者特征。在 59 例（58%）的 34 例中，初始抗生素治疗有反应，而在 59 例（42%）中，有 25 例对抗生素治疗无反应。多变量分析显示肺癌难治性中性粒细胞减少性发热的独立危险因素。这些危险因素是发热性中性粒细胞减少症的严重程度（比值比（OR）6.11；95%置信区间（CI）1.85-20.14）和 C 反应蛋白超过 10 mg/dl（OR 4.39；95%CI 1.22-15.74）。这些因素可以预测发生难治性中性粒细胞减少性发热的肺癌患者的预后。
